|
LIVE WEBINAR: Thursday, September 21, 2023, 5:00 PM – 6:00 PM Eastern Time
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung CancerA CME/MOC-Accredited Live Webinar Register for this complimentary event with the “Register Now” button above, Join us on Thursday, September 21th for this CME/MOC-accredited webinar Faculty
Jamie E Chaft, MD Associate Attending Physician Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, New York John V Heymach, MD, PhD Professor and Chair Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas
Moderator
Neil Love, MD Research To Practice Miami, Florida Thursday, September 21, 2023 Topics to Be Discussed
Target Audience
CE Credit FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Chaft — Consulting Agreements: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Flame Biosciences, Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Regeneron Pharmaceuticals Inc. Dr Heymach — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol Myers Squibb, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. SURVEY PARTICIPANTS — Mark Awad, MD, PhD — Information pending. Patrick Forde, MD — No relevant conflicts of interest to disclose. Ramaswamy Govindan, MD — No relevant conflicts of interest to disclose. Heather Wakelee, MD, FASCO — Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Genentech, a member of the Roche Group (uncompensated), Merck (uncompensated), Mirati Therapeutics Inc; Contracted Research: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Clovis Oncology, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Merck, Novartis, Seagen Inc, Xcovery; Nonrelevant Financial Relationship: ECOG-ACRIN (executive committee). MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck. |